Literature DB >> 3821937

Actions of the novel thromboxane A2 antagonists, ONO-1270 and ONO-3708, on smooth muscle cells of the guinea-pig basilar artery.

M Fujioka, T Nagao, H Kuriyama.   

Abstract

The effects of the novel thromboxane A2 (TXA2) antagonists, ONO-1270 and ONO-3708, on the electrical and mechanical responses evoked by various agents, and in particular 9,11-epithio-11,12-methano-thromboxane A2 (STA2), were investigated in the guinea-pig artery. STA2 (up to 0.3 microM), and ONO-1270 and ONO-3708 (up to 1.0 microM) did not modify the membrane potential in smooth muscle cells. Perivascular nerve stimulation induced an excitatory junction potential (e.j.p.), and with frequencies over 0.25 Hz, depression of e.j.ps occurred. STA2 (0.1 microM) and both ONO-1270 and ONO-3708 had no effect on these electrical events. STA2 (over 0.1 microM) produced phasic and tonic contractile responses, in a concentration dependent manner. Both ONO-1270 and ONO-3708 competitively inhibited the phasic contraction induced by STA2 as estimated from parallel shifts in the dose-response curve, and from the Lineweaver-Burk and Schild plots (the PA2 values were 8.22 for ONO-1270 and 8.70 for ONO-3708), but both agents inhibited non-competitively the PGF2 alpha-induced contraction. ONO-1270 and ONO-3708 (up to 0.1 microM) had no effect on contractions induced by K+ and caffeine, but did slightly inhibited contractions induced by 5-hydroxytryptamine (5-HT). Following application of indomethacin, neither agent modified the 5-HT-induced contraction. In Ca2+-free solution, 10 nM STA2 produced a phasic but not a tonic contractile response. ONO-1270 and ONO-3708 (over 1 nM) inhibited this phasic contractile response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3821937     DOI: 10.1007/bf00569388

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  Elevation of cytoplasmic free calcium concentration by stable thromboxane A2 analogue in human platelets.

Authors:  Y Kawahara; J Yamanishi; Y Furuta; K Kaibuchi; Y Takai; H Fukuzaki
Journal:  Biochem Biophys Res Commun       Date:  1983-12-28       Impact factor: 3.575

2.  Competitive antagonism at thromboxane receptors in human platelets.

Authors:  R A Armstrong; R L Jones; V Peesapati; S G Will; N H Wilson
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

3.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

4.  Excitation--contraction coupling in smooth muscle cells of the guinea-pig mesenteric artery.

Authors:  T Itoh; H Kuriyama; H Suzuki
Journal:  J Physiol       Date:  1981-12       Impact factor: 5.182

5.  Thromboxane receptor antagonist properties of SQ 27,427 in the anesthetized guinea pig.

Authors:  R Greenberg; T E Steinbacher; D N Harris; M F Haslanger
Journal:  Eur J Pharmacol       Date:  1984-08-03       Impact factor: 4.432

6.  Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.

Authors:  A M Lefer; E F Smith; H Araki; J B Smith; D Aharony; D A Claremon; R L Magolda; K C Nicolaou
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

7.  Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.

Authors:  M L Ogletree; D N Harris; R Greenberg; M F Haslanger; M Nakane
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

8.  Actions of indomethacin and prostaglandins on neuro-effector transmission in the dog trachea.

Authors:  Y Ito; K Tajima
Journal:  J Physiol       Date:  1981       Impact factor: 5.182

9.  Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581.

Authors:  T Sasaki; S Wakai; T Asano; K Takakura; K Sano
Journal:  J Neurosurg       Date:  1982-07       Impact factor: 5.115

10.  Nimodipine inhibits carbocyclic thromboxane-induced contractions of cerebral arteries.

Authors:  R Towart; E Perzborn
Journal:  Eur J Pharmacol       Date:  1981-01-16       Impact factor: 4.432

View more
  3 in total

1.  Involvement of thromboxane and leukotriene in arachidonate induced coronary constriction in diabetic rats.

Authors:  Y Takiguchi; K Umemura; H Hashimoto; M Nakashima
Journal:  Diabetologia       Date:  1989-06       Impact factor: 10.122

2.  Evidence for thromboxane receptor mediated contraction of guinea-pig and human airways in vitro by prostaglandin (PG) D2, 9 alpha,11 beta-PGF2 and PGF2 alpha.

Authors:  R L Featherstone; C Robinson; S T Holgate; M K Church
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

3.  Contraction of the rat isolated aorta caused by Clostridium perfringens alpha toxin (phospholipase C): evidence for the involvement of arachidonic acid metabolism.

Authors:  Y Fujii; J Sakurai
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.